The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

COMPPARE Principal Investigator Nancy Price Mendenhall, MD, FACR, FASTRO, was invited to speak at the sixth annual Biennial Science of Global Prostate Cancer Disparities in Black Men Conference, held virtually November 10-13, 2021. The Prostate Cancer Transatlantic Consortium launched the event in Jacksonville, FL in 2010. Funded by the National…

The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort. The 900th patient was enrolled by the Proton Therapy Treatment & Research Center of the Loma Linda University Medical…

The COMPPARE team was pleased to announce on November 13, 2020 that the study had enrolled 1,000 patients, one-third of its 3,000-patient goal. COMPPARE’s partner site, the James M. Slater, MD Proton Treatment & Research Center, Loma Linda, CA, enrolled the 1,000th patient. COMPPARE stands for “A Prospective COMparative Study…

English Version Download PDF Spanish Version Download PDF…

Thank you for helping future patients Participants: Stay Current Your continued participation in COMPPARE is vital to our success.

Thank you for your interest in the COMPPARE study. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and approved by the University of Florida Institutional Review Board…

Thank you for your interest in the COMPPARE study. Patient enrollment is now closed. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study is funded by the Patient-Centered Outcomes Research Institute (PCORI) and led by…

Participation Flow Chart Steps taken by patients who are eligible for COMPPARE. View the participation flow chart. Study Flow Chart…

Study Overview What is COMPPARE? What is the goal of COMPPARE? Why is COMPPARE important for patients? Information for Participants   What is COMPPARE? COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).”…